SPTLC2

Across TCGA pan-cancer cohorts, SPTLC2 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated SPTLC2 data layer compared with 12 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SPTLC2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated SPTLC2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and LUSC show a favorable association.

KIRC, ACC, and LUSC are the cancer types where SPTLC2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.719	0.543	<.001	75	view →
ACC	DFS	Median	All	0.257	0.644	<.001	40	view →
LUSC	DFS	Quartile	All	0.860	0.668	.003	38	view →
LIHC	OS	Quartile	All	0.439	0.618	.005	37	view →
MESO	DFS	Tertile	III,IV	0.233	0.491	.008	37	view →
LGG	OS	Median	All	0.759	0.859	.002	27	view →
PAAD	DFS	Quartile	All	0.164	0.395	.001	26	view →
SCLC	OS	Quartile	III,IV	0.693	0.236	.005	25	view →
UVM	DFS	Median	All	0.444	0.717	.003	24	view →
PRAD	DFS	Tertile	All	0.908	0.671	<.001	18	view →
HNSC	OS	Tertile	III,IV	0.319	0.645	.002	14	view →
LAML	DFS	Tertile	All	0.281	0.538	.048	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

SPTLC2–KIRC (OS)

Open the KIRC breakdown →